Log in

Seed and Angel Financing

  • 17 Nov 2015
  • 6:00 PM - 9:00 PM
  • Microsoft Technology Center, One Camb ridge Center (Kendall Square, next to Marriott Hotel), Cambridge, MA.


Meeting Presentations

Michael Gladstone, Atlas Venture - presentation
Carl Berke, Partner, Partners HealthCare - presentation

Catherine Friend White, Managing Director, Golden Seeds - presentation

Discover how Angel and Seed investors approach the problem of making a good investment. Go behind the scenes of the decision making to discover the process our panelist-investors use to choose and to invest in emerging and seed stage companies.  Whether you are planning to launch a company or you are planning the next level, a Seed or Angel investor could be the funding source you are looking for. Maybe you’re not even sure what angel investment is? This panel will focus on the nature of angel and seed investments in New England technology based companies, and on how to obtain that initial angel or seed-stage investment in your company. Two of the speakers will be investors in early stage life science companies and the third speaker an investor in other early stage companies. The panelists will also offer candid views and discussion on how to prepare a company for raising angel capital or seed stage investment, the raise itself, and how to work with angel groups or seed investors after getting the investment


Michael Gladstone, Atlas Venture, http://atlasventure-ls.com

Michael Gladstone is a principal at Atlas Venture, where he focuses on new company creation. Michael has been involved in building several Atlas Venture-originated companies, including Spero Therapeutics, Padlock Therapeutics, and Surface Oncology. He has also been closely involved with Atlas’s immuno-oncology investments CoStim Pharmaceuticals (acquired by Novartis) and Unum Therapeutics.

Prior to joining Atlas in 2012, Michael was a senior associate consultant at L.E.K. Consulting, where he focused on business development and corporate strategy for biopharma clients. Previously, Michael worked in the Viral Pathogenesis department of Beth Israel Deaconess Medical Center under Professor Norman Letvin. His research focused on elucidating the role of interleukin-21 in CD8+ T cell memory response to viral antigens.

Michael received an AB in biochemical sciences with highest honors from Harvard College, where he graduated magna cum laude and was awarded the Harvard College Scholarship. 

Carl Berke, Partner, Partners HealthCare, http://innovation.partners.org

Carl is a Partner at Partners HealthCare Innovation Fund in Boston, investing in new biomedical technologies emerging from Massachusetts General Hospital and Brigham & Womens Hospital. He is also currently a Founding Director of Mass Medical Angels LLC, a local investment group dedicated to seed stage investment in biomedical innovation. His career has spanned over 25 years in the practice and management of innovation to bring new technologies from lab to market. As a bench scientist and R&D director, he worked at Polaroid Corporation and Hygeia Sciences in the development of photographic and clinical products – he is an inventor on 6 US patents. He served as a Partner at Integral/Analysis Group, a management consultancy focused on innovation and growth strategy. He has served on the boards of Quosa [literature management software], Kasalis [robotics], Annovation [novel anesthetics], Combinent [drug delivery], Sebacia [acne treatment], Infobionic [cardiac monitoring], QPID Health [bioinformatics], LifeImage [diagnostic image sharing], Syntimmune [autoimmune therapy], Argo Cardiovascular and the Sudanese Education Fund [philanthropy]. Carl holds an AB degree from Cornell University and received his PhD in Organic Chemistry from the University of California at Berkeley. He also holds an appointment as Lecturer in the Biomedical Enterprise Program in the Harvard-MIT Division of Health Sciences and Technology.

Catherine Friend White, Managing Director, Golden Seeds

She is an angel investor and entrepreneur.  Her career in investment management spans three decades, most recently as founder and president of FinArc, LLC (www.finarc.com).  Her investments include companies in marketing, technology, big data and life sciences. Previously she was on the start-up team for International Heritage where she managed a growth and income mutual fund.  White is a director of FinArc Investments, Inc. and the Cutler Center for Investments and Finance. She was a director of BostonFed Bancorp (BFD: American Exchange), Babson College, and other institutions.

She holds the MBA from the F. W. Olin Graduate School of Management at Babson College. 



Andrew Snyder, Ph.D., Research Scientist, Broad Institute, Cambridge

Andrew Snyder, Ph.D. is a Research Scientist at the Broad Institute ( https://www.broadinstitute.org ) of MIT and Harvard. In his current role, he focuses on finding novel therapeutics for cardiovascular disease in collaboration with Bayer Healthcare.  Prior to working at the Broad, Andy worked at Targanox, Inc, a biotech focused on discovering targeted therapeutics to offset the effects of reactive oxygen species. As part of the initial startup team, Andy was responsible for setting up the biology laboratory, co-developing the proteomics platform and conducting screening assays to identifying targets and inhibitors. Andy completed his post-doctoral training in cancer biology at the Wistar Institute in Philadelphia, PA and was a NRSA NIH/NCI individual award recipient. Andy holds a Ph.D. (Molecular and Cell Biology) and a M.S. degree (Environmental Molecular Biology) from the University of Maryland at Baltimore and a B.S. in microbiology from the University of Maryland at College Park. Andy began volunteering with ENET in 2014.


Robert Adelson, Esq., Partner, Engel & Schultz LLP

Robert Adelson, business and tax attorney at the Boston law firm of Engel & Schultz LLP (www.ExecutiveEmploymentAttorney.com). He is Chairman of IEEE Boston Entrepreneurs’ Network. Rob has been an attorney for over 30 years specialized in business, tax, stock options, employment, contracts, financings, trademarks and intellectual property. Rob began as an associate at major New York City law firms before returning home to Boston in 1985 where he has since been a partner in small and medium sized firms before joining his present firm in 2004. Rob represents entrepreneurs, start-ups and small companies, independent contractors and employees and executives. He has been named among the “Top 20 Boston Startup Lawyers” by ChubbyBrain.com, a website that provides tools for entrepreneurs. Rob has been on the ENET Board since 2002 and Chairman since 2009. He holds degrees from Boston University, B.A., summa cum laude, Northwestern University (Chicago), J.D., Law Review, and New York University, LL.M. in Taxation.

Where: Microsoft Technology Center, One Cambridge Center, Cambridge, MA. 02142 Phone: (781) 487-6400 The One Cambridge Center GENERAL ENTRANCE is on Main Street, Cambridge, across from the Kendall Square Post Office. Exit Kendall Square T Station to Main Street. Once you exit the station, head down the Marriott side of Main Street going in the direction of Boston/the Longfellow Bridge. The One Cambridge Center entrance is located next to the Boston Properties entrance. Enter through the glass revolving door and proceed to the Microsoft facilities on the second floor. Note: There is also a direct Microsoft entrance across from the rotary at the confluence of Main Street and Broadway. See also: http://www.microsoft.com/en-us/mtc/locations/boston_directions.aspx

Note: There is also a direct Microsoft entrance across from the rotary at the confluence of Main Street and Broadway.

Admission: General admission is $10. Free to ENET members. Free Pizza and soft drinks will be served. Advanced registration is requested.